Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Identifieur interne : 006025 ( Main/Exploration ); précédent : 006024; suivant : 006026Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Auteurs : Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse]Source :
- Movement Disorders [ 0885-3185 ] ; 1992.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Bromocriptine (therapeutic use), D1‐receptor agonists, Dopamine agonists, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Indoles (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Phenanthridines (therapeutic use), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Receptors, Dopamine D1.
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , physiology : Receptors, Dopamine.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Indoles, Phenanthridines.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Receptors, Dopamine D1.
Abstract
A selective dopamine D1‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1‐receptor stimulation may result in improvement of motor disability in PD.
Url:
DOI: 10.1002/mds.870070309
Affiliations:
- Finlande, France, Royaume-Uni, Suisse
- Angleterre, Finlande occidentale, Île-de-France
- Paris, Toulouse, Turku
- Hôpital de la Salpêtrière, Université de Turku
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F94
- to stream Istex, to step Curation: 002F94
- to stream Istex, to step Checkpoint: 004218
- to stream PubMed, to step Corpus: 004D63
- to stream PubMed, to step Curation: 004D63
- to stream PubMed, to step Checkpoint: 004D54
- to stream Ncbi, to step Merge: 000F20
- to stream Ncbi, to step Curation: 000F20
- to stream Ncbi, to step Checkpoint: 000F20
- to stream Main, to step Merge: 009308
- to stream Main, to step Curation: 006025
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease</title><author><name sortKey="Emre" sort="Emre" uniqKey="Emre" last="Emre">Emre</name></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:60B926BEB9684EE72D9E09F83E49236DC2BB3CE3</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1002/mds.870070309</idno><idno type="url">https://api.istex.fr/document/60B926BEB9684EE72D9E09F83E49236DC2BB3CE3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F94</idno><idno type="wicri:Area/Istex/Curation">002F94</idno><idno type="wicri:Area/Istex/Checkpoint">004218</idno><idno type="wicri:doubleKey">0885-3185:1992:Emre:effects:of:a</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:1535688</idno><idno type="wicri:Area/PubMed/Corpus">004D63</idno><idno type="wicri:Area/PubMed/Curation">004D63</idno><idno type="wicri:Area/PubMed/Checkpoint">004D54</idno><idno type="wicri:Area/Ncbi/Merge">000F20</idno><idno type="wicri:Area/Ncbi/Curation">000F20</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F20</idno><idno type="wicri:doubleKey">0885-3185:1992:Emre M:effects:of:a</idno><idno type="wicri:Area/Main/Merge">009308</idno><idno type="wicri:Area/Main/Curation">006025</idno><idno type="wicri:Area/Main/Exploration">006025</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease</title><author><name sortKey="Emre" sort="Emre" uniqKey="Emre" last="Emre">Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Hôpital Purpan, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The National Hospital for Nervous Diseases, London</wicri:cityArea></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hĉpital de la Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1992">1992</date><biblScope unit="vol">7</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="243">243</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">60B926BEB9684EE72D9E09F83E49236DC2BB3CE3</idno><idno type="DOI">10.1002/mds.870070309</idno><idno type="ArticleID">MDS870070309</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Bromocriptine (therapeutic use)</term><term>D1‐receptor agonists</term><term>Dopamine agonists</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Indoles (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Phenanthridines (therapeutic use)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Indoles</term><term>Phenanthridines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Receptors, Dopamine D1</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A selective dopamine D1‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1‐receptor stimulation may result in improvement of motor disability in PD.</div></front></TEI><affiliations><list><country><li>Finlande</li><li>France</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Angleterre</li><li>Finlande occidentale</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Toulouse</li><li>Turku</li></settlement><orgName><li>Hôpital de la Salpêtrière</li><li>Université de Turku</li></orgName></list><tree><country name="Suisse"><noRegion><name sortKey="Emre" sort="Emre" uniqKey="Emre" last="Emre">Emre</name></noRegion><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name></country><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name></region></country><country name="France"><noRegion><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name></noRegion><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006025 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006025 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:60B926BEB9684EE72D9E09F83E49236DC2BB3CE3
|texte= Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |